| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2017 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Amryt Pharma PLC | 10 | Q1 2023 | 46.3% |
| Progenity Inc. | 9 | Q4 2022 | 69.2% |
| Progenity Inc. | 8 | Q3 2023 | 39.2% |
| RVL PHARMACEUTICALS PLC | 8 | Q3 2023 | 11.5% |
| Societal CDMO Inc. | 8 | Q4 2022 | 3.1% |
| Omeros Corp | 7 | Q3 2023 | 39.3% |
| CAREMAX INC | 7 | Q4 2022 | 27.5% |
| Omeros Corp | 7 | Q3 2023 | 9.9% |
| PUMA BIOTECHNOLOGY INC | 7 | Q3 2023 | 4.2% |
| AEGERION PHARMACEUTICALS INC | 6 | Q1 2019 | 88.7% |
View Athyrium Capital Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PROGENITY, INC. | August 27, 2021 | 4,211,977 | 2.7% |
View Athyrium Capital Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR/A | 2023-05-16 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Athyrium Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.